Role of MPE in Clinical Trials

8. april 2020 - Heidi S. Rønde

ANNOUNCEMENT
A NEW WG ON THE ROLE OF MEDICAL PHYSICIST EXPERTS IN CLINICAL TRIALS

CALL FOR MEMBERS IS OPEN FOR CANDIDATES
The EFOMP hereby announces a new Working Group (WG) entitled “Role of MPE in clinical trials”.
The WG will operate under Scientific Committee from 25th June 2020 to 14th June 2022.
The rationale of the WG: To develop a consensus guidance document for the work MPEs do in
clinical trials across Europe. The document will complement the work by American colleagues in
AAPM TG 113. In addition, the document will aim to complement any MPE guidance from National
Member Organisations. Furthermore, the document will aim to cover external beam radiotherapy,
brachytherapy, nuclear medicine / molecular radiotherapy and imaging. Including all of these areas
should enable the WG to cover all current and emerging areas of the role of an MPE in clinical
trials. Considerations will be made for the ethics of MPEs working in clinical trials. This will include,
but is not limited to, general advice and appropriate use of anonymized data.
The suggested chair of the WG is Natalie Abbott (UK).
The expected outcome is a guidance document on the role of the MPE in clinical trials for the
medical physics community.
The targeted audience is EFOMP members, medical physics community in general, clinical trials units, other professionals working in trials involving radiation.

Se mere her.

Interesseret? Skriv til bestyrelsen senest d. 25. maj 2020 . Vi har mulighed for at indstille ét medlem til hver af de tre positioner: Member, Consultant, Observer.

 

 

Skriv en kommentar

Du skal være logged ind for at deltage i debatten. Du kan logge ind her